Evidence map›Paper›PMID 27535719›Full record

ArticleEpidemiology and infection2016

Impact and long-term protection of hepatitis B vaccination: 17 years after universal hepatitis B vaccination in Tunisia.

H Chaouch, W Hachfi, I Fodha, O Kallala, S Saadi, A Bousaadia, F Lazrag, I Bougmiza, M Aouni, A Trabelsi and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Epidemiology and infection, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

H ChaouchDepartment of Infectious Diseases,University Hospital Farhat Hached,Sousse,Tunisia.
W HachfiDepartment of Infectious Diseases,University Hospital Farhat Hached,Sousse,Tunisia.
I FodhaLR14SP02;Laboratory of Microbiology,University Hospital Sahloul,Sousse,Tunisia.
O KallalaLR14SP02;Laboratory of Microbiology,University Hospital Sahloul,Sousse,Tunisia.
S SaadiLR14SP02;Laboratory of Microbiology,University Hospital Sahloul,Sousse,Tunisia.
A BousaadiaViral Hepatitis Research Unit (UR12SP35),University Hospital Farhat Hached,Sousse,Tunisia.
F LazragViral Hepatitis Research Unit (UR12SP35),University Hospital Farhat Hached,Sousse,Tunisia.
I BougmizaDepartment of Community Medicine,University of Sousse,Sousse,Tunisia.
M AouniLaboratory of Infectious Diseases and Biological Agents,Faculty of Pharmacy,University of Monastir,Monastir,Tunisia.
A TrabelsiLR14SP02;Laboratory of Microbiology,University Hospital Sahloul,Sousse,Tunisia.
E Ben JaziaViral Hepatitis Research Unit (UR12SP35),University Hospital Farhat Hached,Sousse,Tunisia.
A LetaiefDepartment of Infectious Diseases,University Hospital Farhat Hached,Sousse,Tunisia.
Hôpital Farhat Hached · TNHôpital Sahloul · TNLondon Rebuilding Society · GBUniversity of Monastir · TNUniversity of Sousse · TN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis B virus (HBV) vaccination has been part of the Expanded Programme of Immunization (EPI) in Tunisia since 1995. The aim of this study was to evaluate, for the first time, the impact of mass vaccination in Tunisia 17 years after this programme was implemented, and in parallel, assess the long-term persistence of anti-HBs antibody in the vaccinated Tunisian population. A total of 1422 students were recruited (703 vaccinated, 719 non-vaccinated). HBV seromarkers were checked. None of the students from either group had positive HBsAg. The overall prevalence of anti-HBc was 0·8%. A Significantly higher prevalence of anti-HBc was noted in unvaccinated students than in vaccinated (1·4% vs. 0·3%, P = 0·02). The overall seroprotection rate (anti-HBs titre ⩾10 mIU/ml) was 68·9% in vaccinated subjects. Seroprotection rates and geometric mean titres decreased significantly with increasing age, reflecting waning anti-HBs titre over time. No significant difference was detected between seroprotection rates and gender or students' area of origin. Incomplete vaccination was the only factor associated with an anti-HBs titre <10 mIU/ml. This study demonstrates the excellent efficacy of the HBV vaccination programme in Tunisia 17 years after its launch. However, a significant decline of anti-HBs seroprotection has been observed in ⩾15-year-old adolescents which places them at risk of infection. Additional studies are needed in hyperendemic regions in Tunisia.

Indexed as

Anti-HBs antibodyhepatitis B vaccineprotective immunityTunisia

Identifiers

PMID27535719
PMCPMC9150185
OpenAlexW2513007451

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.